Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The newly certified kits are designed for early detection and large-scale screening programs
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Subscribe To Our Newsletter & Stay Updated